Neuroblastoma is the most common extracranical tumor of childhood and the most deadly tumor of infancy. It is characterized by early age onset and high frequencies of metastatic disease but also the capacity to spontaneously regress. Despite intensive therapy, the survival for patients with high-risk neuroblastoma and those with recurrent or relapsed disease is low. Hence, there is an urgent need to develop new therapies for these patient groups. The molecular pathogenesis based on high-throughput omics technologies of neuroblastoma is beginning to be resolved which have given the opportunity to develop personalized therapies for high-risk patients. Here we discuss the potential of developing targeted therapies against aberrantly expressed molecules detected in sub-populations of neuroblastoma patients and how these selected targets can be drugged in order to overcome treatment resistance, improve survival and quality of life for these patients and also the possibilities to transfer preclinical research into clinical testing.
Introduction
Neuroblastoma is a childhood tumor deriving from progenitor cells of the sympathetic nervous system. Neuroblastoma accounts for 6-10% of all childhood cancers, but for 9-15% of all childhood cancer related deaths and is the most common extracranial tumor of childhood [1] [2] [3] [4] . The median age at diagnosis is 17-18 month and approximately 40% of the patients are younger than 1 year at diagnosis whereas less than 5% of the patients are older than 10 years [2, 3, 5] .
Histopathologically neuroblastoma belongs to the "small blue round cell" neoplasm of childhood, a group consisting mainly of undifferentiated pediatric malignancies. The neuroblastoma tumors arise from neural crest progenitor cells of the sympathoadrenal lineage, called the sympathogonia. Neural crest is a transient structure consisting of multipotent progenitor cells presented during embryogenesis that emerge from the dorsal part of the neural tube and migrate during mid-gestation throughout the body. The progenitor cells are very proliferative and tightly regulated through interplay between different signaling pathways [6, 7] . After migration these pluripotent sympathogonia form the sympa-thetic ganglia, the chromaffin cells of the adrenal medulla, and the paraganglia, reflecting the classic localizations of neuroblastoma [3, 7] .
Neuroblastoma can occur anywhere along the sympathetic nervous system, although generally form in the abdomen along the sympathetic chain and in the adrenal gland medullary region. Neuroblastoma is characterized by an extreme clinical heterogeneity, it spans from spontaneous regression or differentiation, to treatment-refractory progression despite intensive multimodality therapy. The heterogeneity is also reflected in the survival. The overall survival is for patients with low-and intermediate-risk disease 85-90% [8] [9] [10] . However, approximately half of the neuroblastoma patients are diagnosed with high-risk disease with an overall survival of 50% [11] [12] [13] [14] .
In the past decades, significant advances have been made in the understanding of neuroblastoma biology as a result of high-throughput genomic analysis, exome and whole-genome sequencing, genome-wide association studies, transcriptomics and drug screenings. The next phase, presently ongoing, is the translation of the refined understanding of neuroblastoma biology and genetics into improved prognostic stratification and precision medicine. New treatment protocols for neuroblastoma that currently are under development are aimed at identifying predictors for response and outcome as well as discovering molecular aberrations in the tumors that may serve as druggable targets. 
Overview of current neuroblastoma treatment
In order to determine treatment regimens for patients with neuroblastoma, staging systems based on clinical and biological risk factors have been developed. Historically, different staging systems have been operational to determine treatment plans for neuroblastoma patients that have complicated the ability to define the optimal treatment regimen and management of individual patients. However, since 2009 The International Risk Group staging system (INGRSS) based on tumor imaging at the time of diagnosis, has been used to stratify neuroblastoma patients into different risk groups (Table 1 ) [9] .
Treatment of neuroblastoma patients differs widely between the risk groups. Treatment of high-risk (stage M and MS) involves intense induction chemotherapy regimen including cisplatin, vincristine, carboplatin, etoposide and cyclophosphamide (COJEC) [14, 15] . The induction therapy is followed by surgery and myeloablative therapy combined with reinfusion of hematopoietic stem cells and local radiotherapy. Maintenance treatment include retinoic acid in attempt to differentiate the remaining tumor cells and immunotherapy using anti-GD2 in combination with granulocyte macrophage colony stimulating factor (GM-CSF) and interleukin (IL)-2 [16] [17] [18] [19] [20] [21] .
Patients categorized to the intermediate-risk group receive milder chemotherapy followed by surgical resection of the remaining tumor mass. Treatment stratification in the low-risk group aim to be given minimal therapy and some children are cured by surgery alone or no treatment caused by spontaneous tumor regression [18, 20, 21] .
Investigational drugs for the treatment of neuroblastoma
Recent collaborative clinical trials have led to both increased survival for high-risk neuroblastoma and decreased treatmentrelated toxicities in patients with low-and intermediate neuroblastoma. However, the majority of completed or ongoing clinical trials for neuroblastoma still include different combinations, formulas, administration frequencies and concentrations of existing chemotherapeutic drugs that have limited targeted specificity for neuroblastoma (see www.clinicaltrials.gov). Also, a lack of a consensus regarding the definition of clinical response to therapy has hampered the ability to define optimal management and treatment for neuroblastoma patients categorized to different risk groups. Therefore a revision to the International Neuroblastoma Response Criteria has recently been proposed that should ensure a uniform assessment of disease response and interpretation of clinical trial results [22] .
The introduction of chemotherapy in childhood cancer in the 1970-ties has been a success and is together with radiation therapy and surgery the major contributors to the excellent overall survival seen in childhood cancer patients today. However, it is not likely that more intensified and/or combination of existing chemotherapeutic drugs will lead to a significantly further increase in overall survival of childhood cancer patients. Also, the increasing risk for adverse serious late effects must be taken into consideration when designing these trials.
During the last decade, a number of clinical trials have been initiated to identify new treatment options for high-risk neuroblastoma, either with the intention to evaluate effects of new drugs tested in adult cancer patients or to assess new drugs targeting key molecules within signaling pathways of special interest in neuroblastoma, such as MYCN and differentiation. At present 511 clinical trials are registered on www.clinicaltrials.gov in neuroblastoma, only a selection of them will be discussed here (presented with status in Table 2 ). Detailed description of investigational drugs in clinical trials for the treatment of neuroblastoma has recently been described [21, [23] [24] [25] .
Emerging treatment options for neuroblastoma
4.1. The genomic and transcriptomic landscape of neuroblastoma as roadmaps for targeted therapy
The development of fast, reliable and relatively cost effective high-throughput techniques for analyzing genomic DNA and RNA has made possible the detection of targetable DNA mutations or aberrations in transcription of genes which has the potential to be directly transferred to clinical treatment of selected patients. As a consequence of this development a proof-of-concept study to stratify targeted therapies adapted to molecular profiling (MAPPYACTS) of pediatric cancers including neuroblastoma (NCT02613962) has been initiated in France. MAPPYACTS will use whole exome sequencing and RNA sequencing supported by methylation array, miRNA expression array and measurement of immuno-modulators in tumor samples as a guide for personalized treatment approaches of pediatric cancer patients. Similar approaches from the New Approaches to Neuroblastoma Therapy (NANT) consortium (NCT02868268), the Genomic Assessment Improves Novel Therapy (GAIN) consortium (NCT02520713), the Next Generation Personalized Neuroblastoma Therapy (NCT02780128) all in the USA, the Individualized Therapy FOr Relapsed Malignancies in Childhood (INFORM) in Germany [26] , iTHER in The Netherlands, SM-PAEDs in The UK, ZERO Childhood Cancer Programme in Australia, The Danish Childhood Cancer Initiative,Genomic Medicine Sweden ( Fig. 1; Supplementary Fig.  S1 ) and the European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors (ESMART; NCT02813135) all of which include molecular characterization of neuroblastomas, have recently been initiated.
Compared to adult tumors, pediatric cancers exhibit significant less genomic aberrations and mutations [27] [28] [29] . The most common chromosomal aberration associated with poor prognosis in neuroblastoma is somatically acquired amplification of the MYCN gene, hemizygous deletions of 1p and 11q, and gain of 17q [2, 4] . Also, high-risk neuroblastomas frequently exhibit genomic rearrangements at chromosomal region 5p15.33 which is located proximal of the telomerase reverse transcriptase gene (TERT) resulting in chromosomal remodeling, DNA methylation and transcriptional upregulation of TERT [30, 31] . Exome-and whole genome sequencing analyses of primary neuroblastoma samples have reported an overall low somatic mutation count (12-18, median 15) with ALK being the most frequent mutated gene (7-10%) [27] [28] [29] . In addition, chromothripsis, PHOX2 B and ATRX mutations have also been detected in a subset of primary high-risk tumors [28, 29] . Finally, members of the Rho family of genes respon- [197] NCT numbers refers to identifier on https://clinicaltrials.gov.
Fig. 1.
Schematic overview of a workflow for identification of therapeutic targets using comprehensive sequencing analysis. Eligible neuroblastoma patients, currently with relapsed or refractory disease, are included after informed consent. DNA is extracted from tumor specimen and matched non-neoplastic material prior molecular analysis. Tumor content is evaluated either from histological assessment or through SNP-microarray. Sequencing can be performed at different levels, ranging from gene panels including only known therapeutic target to whole genome sequencing. The sequencing level will influence the extent of information that could be obtained from processing the data. The obtained data is discussed by specialists in oncology, biology, genetics, pathology, pharmacy and bioinformaticians in order to find a suitable drug match or trial that can be communicated to treating physician.
sible for correct neuritogenesis during development are frequently mutated in primary neuroblastomas [29, 32] . The genomic landscape between primary and recurrent neuroblastoma demonstrate profound differences, which have important implications for designing targeted treatment approaches based on the genetic landscape of the tumor. Detection of intertumoral heterogeneity between locoregional and metastatic tumors from the same patient with recurrent neuroblastoma further complicate the application of targeted therapies for these patients [33] .
Compared to primary tumors recurrent neuroblastomas frequently demonstrate genetic lesions that converge on RAS-MAPK signaling [33] [34] [35] .
Of the genetic aberrations described in neuroblastoma only activating ALK mutations and MYCN overexpression have been proven to be de novo oncogenic drivers as mutation or overexpression of these molecules give rise to neuroblastoma in genetically engineered mouse models [36, 37] . The paucity of somatic mutations and lack of tumor drivers in neuroblastoma limits the opportunities for molecular targeted therapies for patients with this disease.
Targeting ALK in neuroblastoma
The majority of ALK mutations detected in neuroblastoma is point mutation within the kinase domain and commonly induces constitutive activation of the ALK protein [38] [39] [40] [41] [42] . Deletions within the extrachromosomal domain and translocations causing aberrant ALK activation have also been described [43] [44] [45] [46] . The majority of point mutations of ALK is found in one of three hotspots; F1174, F1248 and R1275 of the kinase domain [47] .
Activating mutations of ALK are the most frequent druggable mutations identified in neuroblastoma to date and strong preclinical evidences have been provided that support activation of ALK as an oncogenic driver in neuroblastoma. For instance, overexpression of mutated ALK transformed both NIHT3T cells and murine neural crest cells whereas targeted expression of mutated ALK to the developing neural crest induced neuroblastoma in both zebrafish and mice [37, 40, [48] [49] [50] . Activated ALK also act in synergy with MYCN to drive initiation and progression of neuroblastoma in preclinical models [37, 48, 49] . Treatment of transgenic mice carrying established ALK-driven neuroblastoma with ALK inhibitors induced complete tumor regression and significant tumor growth inhibition was observed in immunodeficient mice carrying human neuroblastoma xenografts harboring activating ALK mutations [37, 38] . These findings establish activated ALK as a highly interesting target for therapy in neuroblastoma harboring mutated or activated ALK.
Although encouraging results were obtained in clinical studies using the first generation ALK inhibitor, crizotinib, for some pediatric cancers, not all neuroblastoma patients having an ALK mutation in their tumor responded to the treatment [51] . There are indications suggesting that ALK F1174 mutations, one of the most common ALK mutations observed in neuroblastoma, are resistant to crizotinib [43, 52] . Therefore, a clinical trial using lorlatinib, an ALK/ROS inhibitor with increased ALK-binding affinity to all mutational variants, has recently opened within NANT (NCT03107988) [53] . Also, pediatric phase I studies of the second-generation small molecule inhibitors of ALK, ceritinib (NCT01742286) and entrectinib (NCT02650401, NCT02097810) are ongoing. Entrectinib has also been confirmed as a promising drug inhibiting TrkB, a neurotrophin receptor highly expressed in unfavorable neuroblastomas [54, 55] . Preclinical studies using new inhibitors of ALK have proven to be highly effective both used as a single agent and in combination with conventional chemotherapeutic drugs or other novel compounds [56] [57] [58] [59] [60] [61] [62] [63] . This provides hope that a cure for high-risk neuroblastoma with deregulated ALK activity will be accomplished in the near future.
Targeting MYCN in neuroblastoma
For the last three decades gene amplification of the oncogenic transcription factor MYCN has been a hallmark indicator for poor prognosis in patients with neuroblastoma [4] . During the same period an intense search for compounds that inhibit MYC (C-MYC, MYCN and MYCL) proteins has been carried out without resulting in the discovery of any drug that directly inhibit these proteins with a clinical relevance for cancer treatment [64, 65] . The main reason is probably the absence of well-defined pockets within the MYC proteins that small molecules can stably attach to and inactivate the DNA binding capacity of the proteins [66] [67] [68] . Therefore, alternative strategies to inhibit the activity of MYCN have been explored.
Inhibition of MYCN function
MYCN requires its partner MAX in order to fully function as a transcriptional activator [69, 70] and efforts to block this interaction has been investigated as a mode to inhibit the activity of MYCN. Two structurally unrelated compounds 10074-G5 and 10058-F4 both blocked the MYCN-MAX interaction and induced differentiation and apoptosis of MYCN amplified neuroblastoma cells [71] . 10058-F4 also suppressed the growth of neuroblastoma tumors in TH-MYCN-driven transgenic mice and MYCN-amplified neuroblastoma cells grown as xenografts in nude mice [72, 73] . Although both 10074-G5 and 10058-F4 specifically block the MYC-MAX interaction in vitro, their solubility and short half-life makes them less efficient in vivo and will likely not been further developed for clinical testing [74, 75] .
Indirect inhibition of MYCN
The most well established methods for inhibiting MYCN activity has been to indirect target MYCN transcription and MYCN protein stability [68, 76] . Bromodomain and extraterminal (BET) proteins are a group of epigenetic modifiers that recruit transcriptional regulatory complexes to acetylated chromatin and affect the transcriptional activity of several genes including MYCN [77, 78] . The small molecule inhibitors of BET proteins, JQ-1, OTX015 and I-BET726 (GSK525762) have been shown to downregulate MYCN expression, induce cell cycle arrest and apoptosis in neuroblastoma cells. These three substances also inhibit the growth of both MYCN-amplified and non-amplified neuroblastoma in murine mouse models [77, [79] [80] [81] [82] . Several clinical trials using OTX015 and I-BET726 have been initiated in adult hematological malignancies and solid tumors [83] . Results from these trials will give guidelines if the small molecule inhibitors will be applicable as a treatment option for patients with MYCN-amplified neuroblastomas.
The MYCN protein has a short half-life of approximately 30 min. The stability of MYCN is controlled by specific phosphorylations at Ser-62 and Thr-58 residues accomplished by cyclin-dependent kinase (CDK1)-Cyclin A/CDK1-Cyclin B1 complexes and GSK-3␤, respectively [84] . The result of these phosphorylation events is rapid Fbxw7 ubiquitin ligase-mediated proteasomal degradation of the MYCN proteins [85, 86] . Aurora A kinase (AURKA) has been shown to stabilize MYCN through complex formation resulting in protection of MYCN from proteosomal degradation [87] . In preclinical models the small molecule inhibitors, MLN8054 and MLN8237 (alisertib), of AURKA were shown to enhance MYCN degradation and alisertib induced complete tumor regression in three out of seven neuroblastoma xenografts in mice [2, 88] . In a phase II study of alisertib, irinotecan and temozolomide in children with relapsed and refractory neuroblastoma an objective response was observed in 19% of the patients [89] .
Activation of the PI3K/AKT/mTOR signaling axis has been shown to predict poor prognosis in neuroblastoma [90] . Inhibitions of key molecules within PI3K/AKT/mTOR signaling increase the activity of GSK-3␤ and enhance MYCN phosphorylation and proteosomal degradation. These inhibitors induce growth arrest and apoptosis of neuroblastoma cells both in vitro and in murine models of neuroblastoma [91] [92] [93] [94] [95] . A phase I/Ib study using the PI3K/AKT inhibitor perifosine has recently been completed. This study was carried out in young adults with advanced solid tumors with a 1b expansion cohort for patients with relapsed and refractory neuroblastomas. Therapy was overall well tolerated and nine out of 24 patients showed a progression free survival for a median of 54 months from study entry [96] .
Similar, we recently demonstrated that mutations in RHO/RAC associated genes induce RHOA and activation of downstream Rhoassociated kinase (ROCK) 1 and 2. Inhibition of ROCK using HA1077 (Fasudil) resulted in GSK-3␤ mediated downregulation of MYCN, neuroblastoma cell differentiation and suppression of neuroblastoma growth in preclinical in vivo models [32] .
Finally, inactivation by silencing of CDK2 is synthetic lethal in neuroblastoma cells overexpressing MYCN and AT7519, a CDK2 specific inhibitor, suppressed the growth of patient-derived MYCN amplified neuroblastoma grown as xenografts in nude mice as well as inhibited neuroblastoma growth in TH-MYCN mice [97, 98] .
Targeting MYCN downstream molecules
A key downstream target of MYCN is ornithine decarboxylase (OCD1) an enzyme involved in cell metabolism by catalyzing the rate limiting step of polyamine biosynthesis and hexokinase [99] . Interestingly, difluoromethylornithine (DMFO; Eflornithine) an ODC1 inhibitor reduced MYCN protein levels in neuroblastoma cells and in combination with SAM486, another polyamine biosynthesis inhibitor, impaired neuroblastoma growth in TH-MYCN mice [100] . These findings not only support the role of MYCN in metabolism, but also suggest that inhibition of polyamine biosynthesis is an alternative for targeting MYCN-driven neuroblastomas. DMFO is clinically approved for the treatment of Trypanosoma brucei gambiense encephalitis (African sleeping sickness) and has in a number of clinical trials been tested as a chemopreventive drug in adult cancer [101] . A phase I study in children with neuroblastoma showed no dose-limiting toxicities [102] . Hence, several clinical trials testing the anti-tumorigenic effects DMFO in neuroblastoma either alone or in combination with chemotherapeutic drugs are currently ongoing (NCT01059071, NCT02559778, NCT02030964, NCT02139397, NCT01586260, NCT02679144, and NCT02395666).
Targeting Ras/MAPK in neuroblastoma
Genetic lesions in the MAPK signaling cascade are detected in 3-5% of primary neuroblastomas [27] . However, 78% (18/23), of relapsed neuroblastoma samples contain mutations, including ALK mutations that are predicted to activate RAS signaling [34, 35] . In addition, signaling through the tyrosine kinase receptors ALK, EGFR and ERBB2, all of which have been found to be non-mutational activated in subsets of neuroblastoma, converge at MAPK. These observations justify the investigation of the effectiveness of drugs targeting the RAS/MAPK signaling axis in neuroblastoma. Indeed, MAPK/ERK kinase (MEK) inhibitors have been shown to inhibit the growth of neuroblastoma cells in vitro [103] . Binimetinib, a MEK1/2 inhibitor acts in synergy with the CDK4/6 inhibitor, ribociclib to suppress tumor growth in a panel of murine xenograft models of neuroblastoma [104] . A recent clinical trial (NCT02780128) investigating the ALK inhibitor ceritinib in combination with ribociclib and the MEK1/2 inhibitor trametinib in relapsed neuroblastoma patients with ALK mutations and/or activating mutations in MAPK signaling have been initiated [104] . Also a phase I/IIa clinical trial using the MEK inhibitor trametinib as single treatment or in combination with dabrafenib in patients with V600 mutations has been initiated in pediatric patients with refractory or relapsed tumors, including 10 neuroblastoma patients (NCT02124772). However, a recent preclinical study advises against trametinib as monotherapy in ALK-addicted neuroblastoma due to increased feedback activation of other signaling pathways including PI3K/AKT in both cell lines and mice xenografts [105] .
Targeting activated signaling pathways in neuroblastoma
In addition to the above described targeted therapies against genetic aberrations, other inhibitors of key molecules in aberrantly activated signaling pathways have been investigated as treatment options in neuroblastoma.
The neurotrophin receptors TrkA and TrkB have important implications for the diverse biology observed in neuroblastoma patients [106] . High expression of TrkA is detected in low-grade neuroblastomas prone to spontaneous regression or differentiation whereas high level of TrkB is associated to high-risk disease and poor survival [107] [108] [109] . The high-risk tumors also express the TrkB ligand brain-derived neurotrophic factor (BNDF) resulting autocrine/paracrine survival [110, 111] . Two pan-Trk inhibitors, GNF-4256 and AZD6918, both demonstrated anti-tumor activity when tested in preclinical in vivo models of neuroblastoma [112, 113] . Moreover, both inhibitors also enhanced the effects of chemotherapeutic drugs, suggesting that inhibition of Trk might be effective in the treatment of neuroblastoma patients with high TrkB expression. Also, entrectinib, an inhibitor of both ALK and TrkB currently applied in clinical trials for pediatric cancers (NCT02097810, NCT02650401) as mentioned earlier, showed potent anti-tumor activity of Trk-driven neuroblastoma in a xenograft mouse model [55] .
Expression of epidermal growth factor receptors (EGFR), more specifically HER1 and HER3 has been found to be expressed in primary neuroblastomas [114] . Addition of EGF to neuroblastoma cells stimulates proliferation whereas EGFR inhibitors are cytotoxic to neuroblastoma cells [114, 115] . However, no response on neuroblastoma growth was observed when the EGFR inhibitor, erlotinib, was tested in a preclinical neuroblastoma xenograft model [116] . Also, clinical testing of the EGFR inhibitors, gefitinib or erlotinib gave limited responses in neuroblastoma patients both as single agents or in combination with chemotherapeutic drugs [117] [118] [119] [120] .
Sorafenib and sunitinib are small molecule inhibitors of multiple intracellular and receptor tyrosine kinases [121] . Both inhibitors have been shown to suppress the growth of neuroblastoma cells in vitro and in preclinical neuroblastoma xenograft models [92, [122] [123] [124] . However, limited or no response of sorafenib has been observed in clinical trials of pediatric solid tumors, including neuroblastoma [125] [126] [127] [128] .
Activation of several of the embryonal signaling pathways has been revealed in neuroblastoma. Both Wnt/␤-catenin and Sonic Hedgehog (SHH) have been described to have elevated levels of expression of key proteins involved in these signaling transduction cascades in high-risk neuroblastoma samples and cell lines lacking MYCN amplification [129, 130] . In preclinical testing SHH inhibitors were shown to inhibit tumor growth, however targeting of the transcription factors GLI demonstrated to be more efficient than targeting of the receptor Smoothened [130, 131] . The GLI inhibitor GANT61 also downregulated MYCN and repressed neuroblastoma growth in vivo [131] . A wide range of small molecule inhibitors targeting different sites in the canonical Wnt/␤-catenin signaling pathway have been developed the last decades, several have been preclinically investigated in neuroblastoma and demonstrated to have tumor growth inhibiting properties [132] [133] [134] . In addition, blocking of Wnt signaling has also recognized to prevent chemoresistance to alkylating drugs by inhibition of MGMT, in neuroblastoma among other diagnoses [133] .
Targeting cell cycle and apoptotic regulators in neuroblastoma
In cancer, including neuroblastoma, both senescence and apoptosis is suppressed [135, 136] . Inactivation or mutation of p53 is a common way that cancer cells have acquired to escape senescence or apoptosis, but also inactivation of checkpoint kinases or abnormalities in proteins involved in apoptosis are important factors that cancer cells use to acquire abnormal growth properties [136] [137] [138] . Neuroblastoma frequently contains functional abnormalities in cell cycle checkpoint kinases, the p53/MDM2/p14 Arf regulatory circuit as well as in proteins controlling apoptosis.
Inhibition of checkpoint kinases as a target option in neuroblastoma
The serine/threonine kinase checkpoint kinase 1 (CHK1) is critical for the initiation of DNA replication and repair [138] . Loss of CHK1 activity impairs DNA replication and repair caused by stalled DNA replication forks, resulting in DNA double-stranded breaks and cell death by replication catastrophe [139] . For neuroblastoma it has been shown that depletion or pharmacological inhibition of CHK1 reduced cell viability [140] and the CHK1 inhibitor, prexasertib, suppressed neuroblastoma growth in preclinical in vivo models [141] . Together, these data support CHK1 as a potential therapy target in neuroblastoma. Indeed, a phase I clinical trial in pediatric patients with recurrent or refractory solid tumors was initiated in 2016 (NCT02808650).
Modulation of p53 activity as a treatment option in neuroblastoma
Mutations in the p53 tumor suppressor gene (TP53) are rarely detected in neuroblastoma at diagnosis [142] . However, approximately 50% of relapsed neuroblastomas show impairment of p53 activity [143] . Several mechanisms for p53 inactivation in relapsed neuroblastoma have been described. These include TP53 missense mutations, MDM2 gene amplification or increased MDM2 expression mediated by MYCN and p14 Arf hypermethylation or deletions, miR-380-5p mediated repression of p53 expression or p53 inactivation by the methyltransferase SETD8 [143] [144] [145] [146] [147] . In addition, the most common chromosomal aberration seen in high-risk neuroblastoma is gain of chromosome 17q [148] . The PPM1D gene located at chromosome 17q23.2 encodes a protein phosphatase 1D (WIP1), which is induced by p53. WIP1 negatively regulates p38MAP kinases and reduce phosphorylation of p53, thereby repressing p53-mediated transcription and apoptosis [149] . Another frequently chromosomal abnormality detected in neuroblastoma is hemizygous deletion of chromosome 1p suggesting the presence of a tumor suppressor gene in this region [150] [151] [152] . Detailed genetic analysis suggests chromodomain helicase DNA binding domain 5 (CHD5) at 1p36.31 to be the best candidate tumor suppressor located in this region [151, 153] . CHD5 controls cell proliferation, senescence and apoptosis through positive regulation of p19Arf/p53 pathway [153] . Hence, a number of evidences suggest that the p53/MDM2/p14 Arf signaling axis is a potential therapy target in neuroblastoma.
The majority of investigations performed to restore p53 activity in neuroblastoma involve inhibition of MDM2. Several MDM2 inhibitors have been described and most of them disrupts the MDM2-p53 interaction and restores p53 function [61] . Several MDM2 inhibitors have demonstrated promising preclinical growth inhibiting effects in neuroblastoma cell lines and xenograft models of neuroblastoma both as a single agent and in combination with conventional chemotherapeutic drugs as well as in combination with the anti-angiogenetic drug, bevacizumab, the BCL2 inhibitor, venetoclax and temsirolimus an inhibitor of mTORC1 [154] [155] [156] [157] [158] [159] [160] [161] [162] . Clinical trials with MDM2 inhibitors are currently ongoing, although so far, none have included pediatric patients.
CDK4/CDK6 inhibition as treatment option in neuroblastoma
Genetic amplifications of CCND1 (Cyclin D1) and CDK4, deletions of CDKN2A as well as overexpression of CCND1, CDK4 and CDK6 have been described in neuroblastoma, suggesting that CDK4/CDK6 may be a potential therapeutic target [29, [163] [164] [165] . Treatment with a dual CDK4/CDK6 inhibitor, ribociclib (LEE001), efficiently reduced neuroblastoma proliferation in vitro and caused tumor growth delay in xenografts in vivo. Ribociclib also induced cell-cycle arrest and senescence as a result of decreased phosphorylation of RB and FOXM1 [166] . A phase I trial in 32 patients with neuroblastoma or rhabdoid tumors treated with ribociclib has recently been completed (NCT01747876).
Targeting anti-apoptotic proteins in neuroblastoma
The anti-apoptotic proteins BCL2 and Survivin are both highly expressed in neuroblastoma and the expression levels correlate to poor prognosis [167] [168] [169] . Initial testing of the BCL2 inhibitor ABT263 showed relatively poor effects in neuroblastoma cell lines and in xenograft models of neuroblastoma in nude mice [170] . However, more recently it was shown that the majority of neuroblastoma cell lines express low levels of BCL2 which is in contrast to what has been observed in clinical neuroblastoma samples and that neuroblastoma cells expressing BCL2 are highly sensitive to anti-BCL2 treatment both in vitro and in vivo [158, 171] . Also, genetic or pharmacologic inhibition of BIRC5 (Survivin) using the locked nucleic acid (LNA) based antisense molecule EZN3042 or the small molecule BIRC5 suppressant YM155 suppressed the growth of neuroblastoma cells [171] [172] [173] [174] . It has also been shown that Survivin enhances glycolysis and drug resistance by altered regulation of the mitochondrial fusion/fission machinery and that inhibition of glycolysis using the hexokinase inhibitor lonidamine or the glucose analog 2-deoxy-d-glucose selectively induce autophagy in cells with abnormal expression of Survivin [175, 176] .
Although both anti-Survivin drugs and glycolysis inhibitors are currently in clinical testing in adult cancer patients, pediatric testing has not yet started [177, 178] .
Targeting epigenetic changes in neuroblastoma
The realization that the epigenetic landscape in cancer cells differ considerably from normal cells has resulted in the development of drugs targeting key molecules involved in the regulation of epigenetic modulators like DNA methylases, histone deacetylases (HDAC), molecules involved in nucleosome modulation and noncoding RNAs [179] . Except for bromodomain inhibitors, described above, inhibitors of histone deacetylases have been most extensively studied in neuroblastoma. Preclinical studies have shown that the pan-HDAC inhibitor panobinostat, the class I, II and IV HDAC inhibitor vorinostat (SAHA) as well as small molecule inhibitors of HDAC8, a class I histone deacetylase, inhibit the growth of neuroblastoma cells in vivo [180] [181] [182] [183] . A phase I/II clinical trial of vorinostat as a single agent and in combination with 13-cisretinoic acid in children with solid tumors showed no responses to vorinostat when given as a single agent. However, one complete response was observed in a neuroblastoma patient when vorinostat was combined with 13-cis-retinoic acid [184] . This combination has therefore been further tested in patients with neuroblastoma (NCT01208454) but no results from this study have been reported. Vorinostat has also been tested in combination with the proteasome inhibitor bortezomib in children with refractory or recurrent solid tumors but no antitumor activity was observed [185] .
Neuroblastoma is a radiosensitive tumour and 131 Imetaiodobenzylguanidine (MIBG) is commonly used as a targeted radiotherapy for metastatic neuroblastoma [186] . MIBG is accumulated in neuroblastoma via the norepinephrine transporter (NET) which is commonly expressed on the surface of neuroblastoma cells [187] . Vorinostat has been shown to sensitize neuoblastoma cells to radiation and to increase the expression of NET resulting in increased uptake of 131 I MIBG in neuroblastoma cells [188, 189] . Based on these preclinical observations vorinostat in combination with 131 I MIBG therapy has been evaluated in a phase I clinical trial [190] and is currently being further evaluated in a randomized phase II study in patients with relapsed or persistent neuroblastoma using the combinations 131 I MIBG + vorinostat or 131 I MIBG + vincristine/irinotecan (NCT02035137).
Immunotherapy for neuroblastoma
The recent advances of immunotherapeutic approaches to treat cancer including neuroblastoma have gained hope for further increased patient survival and reduction of serious late effects. In contrast to adult tumors, neuroblastoma expresses limited numbers of different neoantigens on the tumor cell surface restricting the possibilities for antibody-derived therapies [191] . Disialganglioside (GD2) is a surface glycolipid amply expressed on all primary neuroblastomas regardless of disease stage. Anti-GD2 therapy has for the last 20 years been included in the therapy for high-risk neuroblastoma. Although this has led to an increase in patient survival, the anti-GD2 therapy is still lagging behind other childhood cancers like acute lymphoblastic leukemia and nephroblastoma [192] . A clinical trial from the Children Oncology Group reported an increase in 2-year overall survival by 20% in high-risk neuroblastoma patients treated with a combination of chimeric Ab ch14.18, GM-CSF and IL-2 [193] . Similarly, a European study applying ch14.18/CHO GD2 antibodies produced in Chinese Hamster Ovary (CHO) cells with or without IL-2, also showed an analogous increase in patient survival [17] . Together this has led to an approval of this combined antibody/cytokine therapy for the treatment of neuroblastoma in both the USA and Europe. A more recent clinical trial in children with refractory or relapsed neuroblastoma used a chemo-immunotherapeutic regimen combining irinotecan/temozolomide with dinutuximab, a chimeric anti-GD2 antibody, and GM-CSF [194] . Among the 17 patients randomized to this combination 9 (53%) had an objective response strongly suggesting further evaluation of this treatment regimen in a larger cohort of patients to more accurately define which group of patients that response to this chemo-immuno-therapeutic treatment.
An alternative immunotherapeutic strategy has been to express chimeric antigen receptors (CAR) targeting GD2 on effector T cells [195] . Clinical phase I studies in patients with relapsed or recurrent neuroblastoma showed encouraging results with tumor regression, remission or necrosis in some of the patients [195, 196] . However, results from a recent clinical trial using the same GD2-CAR scFv, but including both CD28 and OX40 as costimulatory domains did not show objective response in any of 11 neuroblastoma patients enrolled at 6 weeks post treatment [197] . The efficacy of GD2-CAR therapy may be hampered by antigen-independent clustering of scFv deriving from dinutuximab on the cell surface resulting in tonic signaling and early CAR T-cell exhaustion when costimulatory domains are present. Also the presence of myeloid-derived suppressor cells may lower the impact of CAR T-cells [198, 199] . Indeed, infiltrating CSF-1R + myeloid cells predict poor clinical outcome in patients with neuroblastoma and neuroblastomas contain an immunosuppressive microenvironment by abundant occurrence of CD163 + M2 polarized macrophages and C11b + myeloid derived suppressor cells [200, 201] . Also, high-risk neuroblastoma patients without MYCN gene amplification have a tumor-associated inflammatory signature facilitating tumor growth, drug resistance and immune evasion [202] [203] [204] . Anti-inflammatory therapy has been shown to inhibit the growth of neuroblastoma cells both in vitro as well as in several preclinical in vivo models [204] [205] [206] [207] [208] . Hence, a combination therapy using immunotherapy together with antiinflammatory drugs may be beneficial. CAR T-cell therapy is still in its initial phases of testing, especially in childhood tumors with new and more powerful immune-modulators and −amplifiers being investigated that may augment the immune responses to these tumors. There are currently several clinical trials ongoing investigating the effects of CAR T-cells in neuroblastoma (https:// clinicaltrials.gov).
Conclusion and future approaches
Despite excellent responses including complete tumor regression and cure of the disease using newly developed targeted drugs in preclinical models of neuroblastoma, the responses observed with these drugs have in the majority of cases been disappointing when transferred to the clinic. The main reasons for this are probably the lack of good biomarkers to predict the on-target effects of a specific drug, the use of preclinical model systems which not accurately reflect the nature of the disease and the fact that many drugs show different effects in rodents and humans. We need to intensify the search for biomarkers that correctly predict the effects of the tailor-made drug. However, this is not straight forward since drug-induced biological changes in the tumor cells and its microenvironment commonly occur and therapy-related markers might change during the treatment [18, 209] . Detailed analysis of potential biomarker will be necessary and biomarker investigations at multiple time points during the duration of the clinical trial might give additional important information on the effectiveness of the drug and for future patient management.
There is also a need for more specific preclinical models for the accurate and realistic validation of drug efficacy. Cell lines and corresponding xenografted neuroblastoma cells in immunocompromised rodents are still the mainstay for analyzing the effects of specific drugs. Although these models have neuroblastoma characteristics, they often lack features that are specific to the patient's tumor. For instance, xenograft models do not have an intact immune system and the tumor cells are frequently injected subcutaneously and not in their original niche. Genetically engineered mouse models do have an intact immune system and the tumor grow in the correct tissue. These models are useful but for neuroblastoma very few such models currently exist. The development of organoid cultures and patient-derived orthotopic xenograft models has been shown to more accurate mimic the original human tumor both phenotypically and genotypic [210] . These models should therefore better predict the effects of specific drugs and could potentially be directly transferred to clinical use given that the toxicity profile is acceptable. The newer immunotherapeutic approaches that currently are under investigation should be expanded and combined with targeted therapies. This will require a new generation of immunocompetent animal models equivalent to humanized mouse models of cancer [211] .
As we acquire more detailed knowledge about the molecular biology and pathogenesis of neuroblastoma and mechanisms of resistance, we will be able to increase treatment precision and develop tailored therapies for those patients that we currently are unable to cure.
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